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ABSTRACT
PURPOSE: Patients with advanced hepatocellular carcinoma (HCC) have limited 
effective therapeutic options. Given the rapid advanced in drug development and 
emergence of novel agents, we analyzed the characteristics and outcomes of HCC 
patients treated on early phase trials with an emphasis on targeted therapies.
METHODS: We reviewed the records of consecutive HCC patients evaluated in 
the Phase I Clinical Trials Program at MD Anderson from March 2004. 
RESULTS: Thirty-nine patients were not treated due to poor performance status 
(n = 22, 56%) and decision to pursue alternate therapies (n = 10, 27%). Of 61 
treated patients (median age, 60 years; median prior therapies, 3), eight patients 
(13%) attained stable disease lasting ≥6 months; four (7%) had a partial response, 
mainly with anti-angiogenic or multikinase inhibitors. Median Phase I progression-
free survival (PFS) was 2.6 months versus 4.4 months (p 0.019) and 4.1 months 
(p 0.27) for their first-, and second-line FDA-approved therapy. Molecular analysis 
showed frequent PTEN loss (10/19 patients, 53%) and P53 mutation (4/4 patients 
tested). On multivariate analysis, independent factors predicting shorter survival were 
white ethnicity/race (p 0.031), cirrhosis (p 0.016), and serum sodium (p 0.0013). 
CONCLUSIONS: In our heavily-pretreated HCC patients, the phase I PFS was 
comparable to that of 2nd-line therapy, highlighting a potential role for clinical trials 
after progression on first-line therapy. The response rate (SD>6 months/PR) of 
20% was observed with early signals of activity in regimens combining inhibitors 
of angiogenesis, multiple kinases and mTOR with preliminary molecular analysis 
revealing prevalence of PTEN loss.
INTRODUCTION
Advanced hepatocellular carcinoma (HCC) remains 
a therapeutic challenge with limited effective treatment 
options. Patients with limited localized disease are 
considered for surgical resection or liver transplantation, 
both of which remain the only potentially curative options.
[1-3] However in patients with recurrent or unresectable 
disease, the mainstay of therapy remains monotherapy 
with sorafenib, an oral multikinase inhibitor of vascular 
endothelial growth factor (VEGF), platelet derived growth 
factor receptor (PDGFR) and RAF.[4, 5] The pivotal 
multicenter, phase 3, double-blind, placebo-controlled 
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trial in 602 patients with advanced HCC demonstrates 
an improvement in the median overall survival (10.7 
months) in the sorafenib group versus the placebo group 
(7.9 months).[6] Multimodal therapeutic approaches 
using arterial embolization or chemoembolization also 
demonstrate a survival benefit over supportive care 
alone in patients with unresectable disease.[7, 8] Recent 
advancements incorporated the use of radioembolization 
with yttrium-90 into the treatment algorithm for 
intermediate to advanced HCC with Child-Pugh class A 
or B.[9-11] With the expanding development of agents 
targeting angiogenesis and aberrant cell signaling, we 
explored the characteristics and outcomes of patients 
with advanced HCC who received treatment on a phase I 
clinical trial with an emphasis on targeted therapies.
RESULTS
Patients characteristics
Of the 100 patients with HCC referred to the Phase 
I Clinical Trials program, 39 patients were not enrolled 
in a phase I clinical trial due to poor performance status 
(ECOG >3, N = 22, 56%), decision to pursue alternate 
therapies including treatments closer to home (N = 10, 
26%), no evidence of disease post-resection (N = 3), 
prohibitive lab abnormalities (N = 2) and insurance denial 
(N = 2). 
Overall, 61 patients who participated in a phase I 
trial are included henceforth in this analysis. Pretreatment 
characteristics at presentation to the Phase I clinic are 
summarized in Table 1. The median age at diagnosis was 
60 years (range, 11-84 years). There were 12 women and 
49 men of whom 30 (49%) were White, 11 (18%) Asian, 
10 (16%) African American, and 10 (16%) of Hispanic 
origin. Eleven patients (18%) had an ECOG PS of 0, 49 
patients (80%) had a PS of 1 and 1 (2%) patient a 2. The 
median number of metastatic sites was 2 (range 0-5). 
The most common sites of metastases at time of Phase I 
referral were liver (N = 49, 80% of patients), lymph nodes 
(N = 31, 51%), lung (N = 25, 41%), peritoneum (N = 14, 
23%), bone (N = 13, 21%), adrenal (N = 8, 13%), and 
other (ovary, pancreas, spleen; N = 3, 5%). Regarding the 
extent of liver disease, 41 patients (37%) were classified 
as modified Child-Pugh class A while the remaining 20 
(33%) had Class B disease. 
Figure 1: Waterfall plot showing the best responses to phase I therapy per RECIST.
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Table 1: Patient characteristics
N %
Gender
Male 49 80%
Female 12 20%
Age at time of diagnosis
Median (range) 60.2 (11.3-83.5)
Race/Ethnicity
White 30 49%
Asian 11 18%
Hispanic 10 16%
African American 10 16%
ECOG Performance Status
0 11 18%
1 49 80%
2 1 2%
Underlying liver pathology
Hepatitis C 20 33%
Alcohol abuse 16 26%
Hepatitis B 20 33%
Steatohepatitis 11 18%
Autoimmune hepatitis 3 5%
Hemochromatosis 1 2%
None 7 11%
Comorbidities
Diabetes 16 26%
Hyperlipidemia 9 15%
Coronary artery disease 8 13%
Imaging characteristics
Presence of cirrhosis 30 49%
Presence of ascites 21 34%
Portal hypertension 17 28%
Portal vein thrombosis 29 48
Lobar distribution
Unilobar 25 41%
Bilobar 36 59%
Distribution
Solitary 6 10%
Multifocal 55 90%
# of metastatic sites, median (range) 2 (0-5)
Metastatic sites 
Liver 49
Lymph nodes 31
Lung 25
Peritoneum 14
Bone 13
Adrenal 8
Other 3
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Therapy before enrollment on phase I trials
Overall, of the 61 patients enrolled on a phase I trial, 
four patients had received no prior therapy because of the 
unavailability of reasonable, conventional therapy for the 
extent of their disease or patient desire to pursue clinical 
trial. The remaining 57 patients had a median of 3 prior 
systemic therapies before referral to the phase I clinic 
(range, 1 – 8). Twenty six patients (43%) also underwent 
a prior chemoembolization, 17 (28%) a surgical resection, 
12 (20%) yttrium-90 radioembolization, 12 (20%) 
radiation, 8 (12%) a radiofrequency ablation, and 3 (5%) 
an orthotopic liver transplantation.
For their first-line treatment in the advanced/
metastatic setting, 41 of 61 patients received a sorafenib-
based regimen, of whom 39 received single-agent 
sorafenib while 2 received sorafenib in combination 
with erlotinib. Three patients received erlotinib 
plus bevacizumab; 5 received a capecitabine-based 
regimen, 4 received a gemcitabine-based regimen, 3 
received platinum combination therapy, and 1 received 
experimental therapy on phase II trial with a novel 
camptothecin analog. 33 patients did not receive a second 
line treatment with FDA-approved agents and instead 
proceeded with a phase I clinical trial. 
Treatment
Overall, patients were initially treated on 1 of 31 
different phase I clinical trials; of these trials, 19 patients 
received therapy on 11 “first-in-human” trials with novel 
targeted inhibitors against VEGFR, kit, cMET, EGFR, 
HER2, CHK1, RAS, organic arsenic or an oleander extract 
derivative.
Of 61 patients, 39 (64%) were treated on a trial 
with combination therapy of two or more agents while 
22 patients (36%) received treatment with a single agent. 
Ten (16%) patients received liver-directed treatment 
with direct infusion of a cytotoxic agent into the hepatic 
artery, of which 2 as a single agent and 8 in combination 
most commonly with bevacizumab. 37 (61%) received 
an oral or intravenous angiogenesis inhibitor, 6 (10%) of 
whom received the anti-angiogenic agent in combination 
with liver-directed chemotherapy. Forty-nine patients 
(80%) received targeted agent(s) alone, nine (15%) 
received targeted agent(s) in combination with cytotoxic 
chemotherapy, and three (5%) received cytotoxic 
chemotherapy alone. The median number of cycles 
Table 2: Characteristics of responses (PR + SD > 6 months)
Pt # Age/Sex Phase I Regimen RECIST response
% change 
in target 
lesions per 
RECIST
Phase I 
PFS (m)
1 54/M Bevacizumab + sorafenib SD -8 9.5
2 63/F HAI Oxaliplatin + IV 5FU, LV + bevacizumab SD -15 11.8
3 74/F Bevacizumab + sorafenib SD -14 10.4
4 56/F Regorafenib
PR (CR of target 
lesions; stable bone 
mets)
-100 27.0+
5 56/M Regorafenib SD 10 7.8
6 73/M Novel inhibitor of HDAC, EGFR1, and Her2 SD 6 11.1
7 57/M HAI paclitaxel
PR (CR of target 
lesions; stable non-
target previously 
embolized liver 
lesions)
-100 41.3
8 49/M HAI Oxaliplatin + IV 5FU, LV + bevacizumab PR -30 6.8
9 58/M Regorafenib SD 8 7.5
10 23/M Bevacizumab + sorafenib SD -23 7.4
11 46/F Pazopanib + everolimus PR -30 8.3
12 68/M Bevacizumab + bortezomib SD 2 6.2
Abbreviations: EGFR epidermal growth factor receptor, FU fluorouracil, HAI hepatic arterial infusion, LV 
leucovorin.
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Table 3: Summary of univariate analysis
Association with PFS Association with OS
 Hazard ratio (95% CI) P-value
Hazard ratio 
(95% CI) P-value
Gender 0.7 (0.4, 1.4) 0.31 0.8 (0.3, 1.7) 0.51
Age at diagnosis 1.3 (0.8, 2.1) 0.35 1.6 (0.9, 2.9) 0.14
ECOG PS 0 vs. 1-2 0.8 (0.4, 1.5) 0.44 1.0 (0.5, 2.1) 0.95
Ethnicity/Race 
(White vs. non-white) 1.2 (0.7, 2.0) 0.47 2.0 (1.0, 3.9) 0.039
Risk factors for chronic liver disease
Alcohol abuse 0.9 (0.5, 1.6) 0.66 0.6 (0.3, 1.2) 0.12
Hepatitis C 1.0 (0.6, 1.8) 0.99 0.7 (0.4, 1.5) 0.38
Hepatitis B 1.2 (0.7, 2.2) 0.47 1.5 (0.8, 2.9) 0.2
Other comorbidities
Coronary artery disease 1.6 (0.7, 3.4) 0.27 1.7 (0.7, 4.4) 0.3
Type II diabetes 0.7 (0.4, 1.3) 0.24 0.8 (0.4, 1.7) 0.6
Extent of chronic liver disease
Cirrhosis 1.9 (1.1, 3.2) 0.016 2.2 (1.2, 4.0) 0.012
Portal hypertension 2.2 (1.2, 4.0) 0.011 2.2 (1.1, 4.4) 0.038
Portal vein thrombosis 1.1 (0.7, 1.8) 0.69 1.2 (0.6, 2.2) 0.57
Ascites 2.1 (1.2, 3.6) 0.012 2.4 (1.2, 4.5) 0.013
Extent of HCC
# of metastatic sites 1.2 (0.7, 2.0) 0.47 1.5 (0.8, 2.8) 0.19
# of prior therapies 0.8 (0.5, 1.4) 0.51 1.0 (0.5, 1.8) 0.96
Baseline laboratory values
Anemia (Hg <10.5g/dL) 0.8 (0.4, 1.6) 0.6 1.3 (0.6, 2.8) 0.57
Elevated LDH (>618IU/L) 1.4 (0.8, 2.4) 0.23 1.9 (1.0, 3.5) 0.051
Thrombocytopenia (<158K/
UL) 0.9 (0.6, 1.6) 0.8 1.1 (0.6, 2.0) 0.8
Elevated alpha-fetoprotein 
(>120) 1.2 (0.7, 2.0) 0.5 1.5 (0.8, 2.8) 0.22
Elevated total bilirubin 
(>1mg/dL) 1.5 (0.8, 2.7) 0.22 2.3 (1.2, 4.6) 0.025
Elevated INR (>1.1) 1.5 (0.9, 2.6) 0.1 1.4 (0.8, 2.7) 0.23
Elevated ALT (>56IU/L) 1.0 (0.6, 1.8) 0.97 0.8 (0.4, 1.5) 0.45
Elevated AST (>46IU/L) 1.5 (0.7, 3.0) 0.26 2.0 (0.7, 5.5) 0.16
Alkaline phosphatase 
>126IU/L 1.5 (0.8, 2.9) 0.24 1.6 (0.7, 3.5) 0.24
Abnormal serum sodium 2.8 (1.2, 6.4) 0.028 3.0 (1.2, 7.4) 0.031
Serum albumin <3.5g/dL 2.8 (1.5, 5.1) 0.0013 5.2 (2.4,11.2) <0.0001
Serum creatinine >1.3mg/dL NR n/a NR n/a
Abbreviations: ALT Alanine aminotransferase; AST Aspartate aminotransferase; ECOG Eastern 
Cooperative Oncology Group; LDH Lactate dehydrogenase; NR not reached; PS Performance status.
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received was two (range 1 – 28). Eighteen patients went 
on to receive therapy under a second phase I trial; of these 
patients, 11 received treatment on 3 phase I trials, 2 were 
treated on a 4th trial.
Response
Fourteen patients were not restaged prior to end 
of cycle 2 due to clinical deterioration and early disease 
progression and are identified on the waterfall plot as 
having a 20% increase in tumor size (Figure 1). Of the 61 
patients treated on studies, 4 (7%) had a partial response 
(PR), 23 had stable disease (38%) including 8 (13%) who 
had SD > 6 months, with a SD > 6 months/PR rate of 20% 
(12 of 61 patients); 10 of these 12 patients received an 
oral or IV inhibitor of angiogenesis. The characteristics 
and specific treatment regimens of these responders 
are detailed in Table 2. Thirty-five patients (57%) had 
progressive disease (PD). The highest response rates (SD 
> 6 months/PR) were observed in patients treated with 
protocols that included agents targeting angiogenesis 
and mTOR. Of 10 patients who were treated on an HAI-
based protocol, 3 (30%) has a significant clinical response 
including two with prolonged SD > 6 months and 1 PR.
One dramatic response was observed in a 56-
year old Asian woman with metastatic HCC in setting 
of hepatitis C, Child-Pugh class A. Her prior therapies 
included sorafenib monotherapy and then a combination 
of bevacizumab plus erlotinib. Upon progression, she 
then enrolled on phase I therapy with regorafenib, then 
a novel oral small molecular inhibitor of VEGFR2 and 3, 
and Ret, Kit, PDGFR and Raf kinases. She demonstrated 
a complete response of target lesions with stable non-
measurable bone lesions, hence deemed a partial response 
per RECIST, and has maintained this remarkable response 
for 27 months ongoing. A second response was observed 
in a 57-year old man who received HAI paclitaxel; he 
demonstrated a complete response of target liver lesions 
with stable post-embolization non-target hepatic masses, 
thereby attaining a partial response.
Survival and toxicities
The median time from diagnosis of advanced/
metastatic disease to date of primary evaluate in the phase 
I clinic was 9.6 months for the 61 patients who enrolled on 
a phase I trials. The median time from the primary phase I 
consultation to beginning therapy on a phase I clinical trial 
was 19 days. The median overall survival from day one 
on a phase I trial was 7 months (95% CI 6, 13). Median 
PFS for 61 treated patients was 2.6 months (95% CI 1.9, 
3.4) on phase I clinical trials. Among these 61 patients, 
the median PFS on their first-line and second-line prior 
therapies with FDA approved agents given in the advanced 
setting was 4.4 months and 4.1 months, respectively. In 
comparison, the PFS on the first line FDA-approved 
therapy given in the advanced setting prior to Phase I 
referral was improved compared to the PFS on phase I 
therapy (p 0.019). However, the second-line therapy with 
FDA-approved drugs was comparable to the PFS on a 
phase I trial (p 0.27). The PFS on first-, second-line and 
Phase I therapy are shown in Figure 2. 
Among the 61 treated patients, 42 (69%) had died 
at the time of analysis. The 90-day mortality was 38% 
with 38 patients alive at 3 months after beginning phase I 
therapy; the 6-month mortality was 61% with 24 patients 
alive at 6 months after beginning therapy on phase I trials. 
Importantly, there was no treatment-related mortality. One 
patient treated on a combination regimen that included 
sorafenib experienced grade 3 hand foot syndrome that 
was not responsive to a dose reduction. This patient 
ultimately showed disease progression on restaging 
imaging. A second patient developed a mild headache, 
dizziness and left-sided visual field blurriness five days 
after beginning a sunitinib-based combination therapy 
and was found to have a small right parieto-occipital 
intracranial hemorrhage, possibly related to therapy. There 
were no other high-grade toxicities reported.
Table 4: Summary of multivariate analysis
 Hazard ratio
Lower 
limit
Upper 
limit P value
Analytic variable associated with shorter PFS
Cirrhosis 1.8 1 3.1 0.038
Portal hypertension 2.2 1.2 4.2 0.017
Abnormal serum sodium 4.3 1.8 10.3 0.0012
Analytic variable associated with shorter OS
White race 2.2 1.1 4.6 0.031
Cirrhosis 2.3 1.2 4.4 0.016
Abnormal serum sodium 4.9 1.9 13 0.0013
Abbreviations: OS overall survival; PFS progression-free survival.
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Prognostic factors for survival
We conducted univariate and multivariate analysis 
to evaluate the effects on survival of variables including 
age, sex, race/ethnicity, ECOG performance status, 
risk factors for liver disease (alcohol abuse, hepatitis C, 
hepatitis B), comorbidities (coronary artery disease, type 
II diabetes), extent of liver disease (presence of cirrhosis, 
portal hypertension, ascites, portal vein thrombosis), 
alpha-fetoprotein; history of thromboembolism; number 
of prior therapies; presence of liver metastases; number 
of metastatic sites; hemoglobin level; platelet count; 
and albumin, lactate dehydrogenase (LDH), alkaline 
phosphatase, bilirubin, alanine aminotransferase, 
aspartate aminotransferase, sodium, and creatinine levels 
(Table 3). Predictors of shorter Phase I PFS in univariate 
analysis were the presence of cirrhosis (p 0.016), portal 
hypertension (p 0.011), ascites (p 0.012), abnormal 
sodium (p 0.028) and hypoalbuminemia (0.0013); these 
five factors also predicted for shorter overall survival (p 
0.012, 0.038, 0.013, 0.031, and <0.0001 respectively). 
The multivariate analysis showed cirrhosis (p 0.038), 
portal hypertension (p < 0.017), and serum sodium (p 
0.0012) as predictors of shorter PFS on phase I therapy 
while cirrhosis, white race and abnormal serum sodium 
predicted for a shorter OS (Table 4). 
Molecular analysis
Testing for mutations in KRAS, NRAS, BRAF, 
CKIT, EGFR, PIK3CA, TP53, MET, GNAQ, AKT1, 
ALK rearrangement as well as immunohistochemistry 
for PTEN loss, ER, and ALK1 and HER-2/neu and MET 
amplification via FISH was completed on patients with 
adequate available tissue in the MD Anderson CLIA-
certified laboratories. On immunohistochemistry, 10 of 
19 tested patients demonstrated an abnormality in PTEN 
expression with 7 tumors showing frank PTEN loss and 
3 samples showing very faint PTEN expression (<10% 
of stained cells). PCR-based DNA sequencing analysis 
was performed in exons 4 to 9 of the TP53 gene. The 
lower limit of detection is approximately one cell bearing 
Figure 2: Progression-free survival of patients treated on phase I trials when compared to their first-line, second-line 
and last systemic antitumor therapy given in advanced setting prior to phase I referral.
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the mutation per five cells (20%). All 4 tested patients 
demonstrated a TP53 aberration, one patient with a 12 
base pair deletion in exon 4 and 3 patients with a missense 
mutation in codon 177 in exon 5 (P177L), codon 158 in 
exon 5 (R158H), and codon 272 in exon 8 (V272M). KIT, 
PIK3CA, and MET mutations were found in individual 
patients. The remainder of the mutational analyses was 
negative including KRAS (all 19 tested), PIK3CA (17 of 
18 tested), BRAF (all 17 tested), and EGFR (all 13 tested). 
DISCUSSION
Unresectable hepatocellular carcinoma in the 
setting of Child-Pugh class A or B liver disease remains 
a clinical challenge particularly after relapse on sorafenib 
given in the metastatic setting. Alternate recommended 
options include locoregional therapy with transarterial 
chemoembolization, conformal or stereotactic radiation, 
or clinical trial.[13] Multimodal approaches include 
liver-directed therapies such as embolization with the 
radionuclide yttrium-90.[14] However, for the patient with 
extrahepatic disease, the need for novel targeted systemic 
therapies and combination regimen is self-evident.
In our analysis, patterns of early signals suggesting 
clinical activity emerged in regimens that target 
angiogenesis particularly in combination with multikinase 
inhibition using sorafenib. Of particular interest is the 
observation of clinical response using a combination of 
bevacizumab and sorafenib in our HCC patients who 
have all previously received single-agent sorafenib. 
These patients had demonstrated disease regression 
with sorafenib monotherapy given as frontline agent 
in the metastatic setting but subsequent development 
of secondary resistance with disease progression. This 
concept of successful retreatment after initial response 
and subsequent progression has been explored in small 
case series and provides an intriguing challenge to the 
prevailing convention that a resistant tumor is unlikely 
to respond to a rechallenge with a similar regimen.
[15, 16] Additional response signals were observed in 
regimens utilizing intravenous angiogenesis inhibition 
in combination with liver-directed infusion of cytotoxic 
chemotherapy. Indeed ten of the twelve prolonged 
responders received an angiogenesis inhibitor, of which 
two were in combination with hepatic arterial infusion 
therapy. 
For the clinician faced with the relapsed advanced 
HCC patient, the timing of referral for a clinical trial 
remains essential point of decision. In our analysis, 
frontline therapy with sorafenib given in the advanced 
setting prior to phase I referral had an improved PFS 
in comparison to the PFS in phase I clinical trial. 
However the PFS on the second line therapy with FDA-
approved agents given in the advanced setting prior to 
phase I referral was comparable to the PFS on phase 
I trial. Furthermore, in our analysis, of the 100 patients 
referred for phase I trials, 39% were ineligible mainly 
due to decline in performance status (ECOG PS of 3 or 
greater) and prohibitively abnormal laboratory values, 
underscoring the importance of early participation in 
clinical trials after progression on frontline therapy in the 
metastatic setting. 
Overall, the pattern of molecular aberrations 
seen in HCC is slowly emerging. In our analysis, the 
most common molecular aberration was observed in 
the expression of the tumor suppressor gene PTEN. We 
observed complete loss or very faint PTEN expression 
in 10 of 19 (53%) of tested tumor samples, highlighting 
the therapeutic target potential of the PI3K/AKT/mTOR 
pathway. Indeed activation of the mTOR signaling has 
been demonstrated in HCC where immunohistochemical 
analysis shows significantly elevated expression of 
p-mTOR in the sinusoidal endothelial cells of HCC 
tissue samples when comparison with non-cancerous 
tissue such as normal liver, cirrhotic nodules, or hepatic 
adenomas.[17, 18] Indeed, preclinical murine models of 
HCC have demonstrated a greater degree of carcinoma 
growth inhibition with the combination of bevacizumab 
plus rapamycin treatment rather than monotherapy with 
either agent.[19] Furthermore, mTOR inhibition with 
rapamycin has been explored in the context of decreased 
post-transplant tumor recurrence in patients receiving 
sirolimus for immunosuppression.[20] Another meta-
analysis investigated 2950 patients with resectable HCC 
who underwent a liver transplantation; among these 
patients, those who were placed on a sirolimus-based 
regimen for immunosuppression had a decreased risk for 
disease recurrence and an improvement in their overall 
survival, highlighting the significant dual role of mTOR 
inhibitors in this selected population.[21] 
Another emerging molecular aberration is mutations 
in the TP53 gene encoding the tumor suppressor protein 
P53. Polymorphisms particularly in codon 72 of TP53 
have been associated with increased risk for multiple 
solid malignancies including high-grade serous ovarian 
and pancreatic adenocarcinoma.[22, 23]
In one series, TP53 mutations have been associated 
with recurrence of HCC; indeed, 16 of 33 cases (49%) of 
recurrent HCC were observed to harbor the P53 mutation; 
additionally patients whose tumor had the P53 mutation 
had a faster time to recurrence after surgical resection, 
further supporting this mutation’s role in carcinogenesis.
[24] 
Our analysis demonstrates several limitations. First, 
a selection bias exists within our patient population given 
that the patients presented with metastatic disease and 
were heavily pretreated prior to the initiation of Phase 
I therapy. Second, a significant number of patients (39 
of 100 referred patients, 39%) were not enrolled on a 
phase I trial for the most part due to poor overall health 
and performance status. Finally, mutational analysis was 
performed in a small subset of patients due to the lack of 
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tissue availability for testing.
Overall, the poor outcomes of advanced HCC 
patients emphasize the need for new approaches. 
Therapeutic strategies on clinical trials with inhibitor 
of angiogenesis and multiple kinases merit further 
exploration in phase II trials.
PATIENTS AND METHODS
Of 3614 patients evaluated in the Clinical Center 
for Targeted Therapy (Phase I Clinical Trials Program) 
at the M.D. Anderson Cancer Center from November 
2004 onwards, we identified 100 consecutive patients 
with HCC. After review of baseline clinical, laboratory, 
radiologic and pathologic data during the initial 
consultation, patients were enrolled on a phase I trial 
based on scientific rationale and protocol availability. 
After initiation of an investigational therapy, patients 
were evaluated at 2- to 4- week intervals, based on the 
specific protocol, with a history, physical examination, 
comprehensive series of laboratory tests, and assessments 
of toxicity and compliance. Restaging scans were done 
every 6-8 weeks, depending on the protocol.
Specific eligibility criteria varied by protocol; 
however, common criteria for participation in most 
phase I clinical trials included presence of metastatic or 
unresectable disease, measurable disease per Response 
Evaluation Criteria in Solid Tumors (RECIST), 
and Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of 0-1 (although a PS of 2 is 
acceptable for certain investigator-initiated studies). 
This study and all clinical trials were approved by the 
Institutional Review Board.
Endpoints and statistical methods
The statistical analysis was performed by our 
biostatistician (K.R.H.). Descriptive statistics summarized 
the patients’ characteristics. Cox proportional hazards 
regression analysis was used to examine the association 
between progression free survival (PFS) and overall 
survival (OS) since beginning phase I therapy and 
the following variables measured at the time of initial 
Phase I consultation: age at diagnosis, gender, ECOG 
PS, etiology of liver disease (alcohol abuse, hepatitis B 
and C, fatty liver disease, etc.), extent of liver disease 
(cirrhosis, portal hypertension, portal vein thrombosis), 
number of metastatic sites, number of prior therapies, 
hemoglobin, lactate dehydrogenase (LDH), platelet count, 
history of thromboembolism, total bilirubin, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (ALK), serum sodium, serum 
creatinine, tumor markers (specifically alpha-fetoprotein), 
and serum albumin. 
Best response was assessed using RECIST every 
2 cycles (6-8 weeks) of therapy as per the protocol.[12] 
Partial response (PR) was defined as a >30% decrease in 
the sum of the longest diameter of target lesions, excluding 
complete disappearance of disease (complete response, 
CR) and progressive disease (PD) was a > 20% increase. 
Stable disease (SD) was defined as changes that did not 
meet the criteria for a PR or PD. Waterfall plot analysis 
according to RECIST is used to illustrate response. 
Overall survival is defined as the date of enrollment 
on a Phase I trial until death from any cause or date of 
last follow-up. PFS is defined as the time from first day of 
treatment on a phase I trial to date off study of last phase 
I trial due to disease progression or death, not toxicity. 
Patients still alive at time of survival analysis and free 
of progression at time of PFS analysis were censored at 
time of last follow-up. Toxicities were assessed using the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events, version per the protocol. A P-value 
<.05 was considered statistically significant. Statistical 
analysis was performed using S-PLUS® 8.0 for Windows 
(Insightful Corp.).
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